AptarGroup beats Q3 sales expectations

AptarGroup

30/10/2025 21:08

Overview

Aptar Q3 sales increase 6%, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company returned $70 mln to shareholders via buybacks and dividends

Outlook

Aptar expects Q4 2025 adjusted EPS between $1.20 and $1.28

Company anticipates strong Pharma segment growth, driven by GLP-1 and biologics demand

Aptar foresees less favorable sales mix due to lower emergency-use system sales

Result Drivers

PHARMA GROWTH - Strong product volume growth in Pharma, especially in injectables, drove sales increase

BEAUTY SEGMENT - Beauty segment sales increased due to currency and acquisitions, but core sales remained flat

CLOSURES CHALLENGES - Closures segment faced lower tooling sales and resin pricing, affecting core sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$961 mln
$953.50 mln (6 Analysts)
Q3 Adjusted EPS
Beat
$1.62
$1.56 (7 Analysts)
Q3 EPS
$1.92
Q3 Net Income
$128 mln
Q3 Adjusted EBITDA
Beat
$223 mln
$212.98 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

Wall Street's median 12-month price target for Aptargroup Inc is $167.00, about 25.5% above its October 30 closing price of $124.36

Press Release: ID:nBw4fn8Ta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)